ACPE Continuing Pharmacy Education
This program has been planned and implemented in accordance with the policies of the Accreditation Council on Pharmacy Education (ACPE) through the joint sponsorship of the Oregon State University College of Pharmacy and the Oregon Society of Health-System Pharmacists (OSHP). The Oregon State University College of Pharmacy is accredited by the Accreditation Council on Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians will receive ACPE Continuing Education Credit. An NABP e-Profile ID is required to receive CPE hours. An NABP e-Profile ID can be obtained at MyCPEMonitor.net. Statement of Credit shall be issued only after successful completion of the program. Successful completion is defined as: 1) Attending, in its entirety, the CPE activity or activities; 2) Participation in the pre-test administered by the presenter; 3) Completion of the online activity evaluation and post-test located at: http://pharmacy.oregonstate.edu/ce within 14 days of program attendance.

Statements of Credit will be uploaded to each participant’s NABP e-profile automatically within 48 hours of successful program completion. It is the participant’s responsibility to complete the online components within 14 days of program attendance to ensure awarding of credit. It is the participant's responsibility to check CPE Monitor and ensure credits have successfully uploaded.

Target Audience: Pharmacists and Pharmacy Technicians
Total Credits Available: 12 hours (1.2 CEUs)
Conflict of Interest Disclosures: None of the speakers or planners for this program have any financial relationships with ineligible companies to disclose.

Title: Aligning Purpose and Meaning in Work to Address Burnout
UAN: 0036-9999-25-200-L04-P/T
Date & Time: Friday, 4/25/25, 1:00 – 2:00 pm
Speaker: Susan Morley, PharmD, MS, MBA, OSU College of Pharmacy, Senior Instructor I, Dept of Pharmacy Practice
Activity-Type: Knowledge-based
Credit Hours: 1.0 (0.1 CEUs)
Learning Objectives:
1. Recognize burnout as an organizational construct
2. List the three dimensions of burnout
3. Describe how low employee engagement impacts the workplace
4. Recognize the importance of creating a purpose-driven culture to promote employee engagement

Title: SGLT-2 Inhibitors and Beyond: The Latest in CKD Drug Advances
UAN: 0036-9999-25-201-L01-P/T
Date & Time: Friday, 4/25/25, 2:05 – 3:05 pm
Speakers: Kathy Sentena, PharmD, OSU College of Pharmacy, Drug Use Research and Management Group, Clinical Pharmacist; Megan Herink, PharmD, Oregon State University, Clinical Associate Professor
Activity-Type: Knowledge-based
Credit Hours: 1.0 (0.1 CEUs)
RPh Learning Objectives:
1. Describe the renal and cardiovascular benefits of SGLT-2 inhibitors in CKD and heart failure patients and review key clinical trials leading to expanded indications
2. Identify other advances in pharmacotherapy for CKD, including finerenone and new data evaluating potential CKD benefits of GLP-1 agonists
3. Evaluate patient-specific considerations and strategies for implementing newer pharmacotherapy in CKD, including eGFR thresholds and interactions with other CKD medications
4. Review policies impacting utilization and access to therapies
CPT Learning Objectives:
1. Identify SGLT-2 inhibitors by generic names
2. Recognize that SGLT-2 inhibitors play a valuable role in CKD in people with and without diabetes
3. Restate that SGLT-2 inhibitors also have beneficial cardiovascular effects in people with and without diabetes

Title: AI and Digital Health in Pharmacy Practice
UAN: 0036-9999-25-202-L04-P/T
Date & Time: Friday, 4/25/25, 3:10 – 4:10 pm
Speakers: Stacey Olstad, PharmD, MBA, OSU College of Pharmacy, Pharmacy Practice Faculty
Activity-Type: Knowledge-based
Credit Hours: 1.0 (0.1 CEUs)
Learning Objectives:
1. Describe the role of AI in healthcare
2. Evaluate the impact of AI and Digital Health on pharmacy practice
3. Recognize ethical and practical considerations in AI implementation

Title: Equitable Care: The Pharmacist’s Impact on Health Disparities
UAN: 0036-9999-25-203-L04-P/T
Date & Time: Saturday, 4/26/25, 8:30 – 9:30 am
Speakers: Kristy Butler, BSPharm, PharmD, MBA, BCACP, Providence St. Joseph Health, Manager, Primary Care & Specialty Clinics and Population Health Clinical Pharmacy Services; Marie Chisholm-Burns, PharmD, PhD, MPH, MBA, FCCP, FASHP, FAST, FNAP, FACHE, Executive Vice President and Provost, OHSU; Yvonne Rice, PharmD, Kaiser Permanente, Senior Administrator, Ambulatory Care & Urgent Care
Activity-Type: Knowledge-based
Credit Hours: 1.0 (0.1 CEUs)
State Requirement: Cultural Competence
Learning Objectives:
1. Define social determinants of health (SDOH), their impact on health disparities, and barriers to their integration in healthcare systems
2. Analyze how health disparities impact patient outcomes and overall quality of life
3. Identify opportunities for interventions and provide real-word examples of pharmacy practice to promote health equity

Title: Menopause is Having a Moment
UAN: 0036-9999-25-204-L01-P/T
Date & Time: Saturday, 4/26/25, 9:45 – 10:45 am
Speakers: Lorinda Anderson, PharmD, BCPS, OSU College of Pharmacy, Clinical Associate Professor
Activity-Type: Knowledge-based
Credit Hours: 1.0 (0.1 CEUs)
Learning Objectives:
1. Differentiate between pre-menopause, perimenopause, menopause, and post-menopause
2. Recognize misinformation related to menopause
3. Review past, present, and future research that has impacts on the treatment of menopause symptoms
4. Identify treatment options for menopausal symptoms that include hormone-based, non-hormone-based, and lifestyle modifications
5. (RPh only) Counsel a patient on what to expect with HRT in menopause symptoms

Title: Buprenorphine for Chronic Pain: Clinical Pearls (Track A)
UAN: 0036-9999-25-205-L08-P/T
Date & Time: Saturday, 4/26/25, 2:00 – 3:00 pm
Speakers: Spencer Potter, PharmD, VA Portland Health Care System, Clinical Pharmacist Practitioner
Activity-Type: Knowledge-based (?)
Credit Hours: 1.0 (0.1 CEUs)
Learning Objectives:
1. Compare and contrast the different formulations of buprenorphine
2. Demonstrate how to initiate buprenorphine formulations for chronic pain in a patient a that is currently utilizing a full mu-opioid agonist
3. Describe relevant buprenorphine patient counseling points

Title: T-Cell Engager Therapies: Considerations for Implementation and Management (Track B)
UAN: 0036-9999-25-206-L01-P/T
Date & Time: Saturday, 4/26/25, 2:00 – 3:00 pm
Speakers: Jack Rasmussen, PharmD, BCOP, OHSU, Pharmacist, Hematology/BMT
Activity-Type: Knowledge-based
Credit Hours: 1.0 (0.1 CEUs)
RPh Learning Objectives:
1. Describe the mechanisms and indications for FDA-approved TCE therapies
2. Compare and contrast the side effect profile of select TCE therapies with chimeric antigen receptor (CAR) T-cell therapy
3. Identify key elements in establishing a safe outpatient program for administration of TCE therapies
CPT Learning Objectives:
1. Describe the common shared side effects of TCE therapies
2. Describe which agents have a REMS and what is needed to dispense TCE therapies
3. Identify possible medication errors while processing TCE orders

Title: Acute Pain Management in Patients with an Opioid Use Disorder (Track A)
UAN: 0036-9999-25-207-L08-P/T
Date & Time: Saturday, 4/26/25, 3:05 – 4:05 pm
Speakers: Emily Skogrand, PharmD, BCPS, OHSU, Addictions Care Specialist
Activity-Type: Knowledge-based
Credit Hours: 1.0 (0.1 CEUs)
Learning Objectives:
1. Describe pain management for patients with opioid use disorder including importance of full opioid agonist and supportive care medications
2. Recognize the importance of treating acute withdrawal in addition to acute pain
3. Describe how to manage acute pain for patients on buprenorphine

Title: A Field Guide to Transplant and Transplant ID Management for the Generalist (Track B)
UAN: 0036-9999-25-208-L01-P/T
Date & Time: Saturday, 4/26/25, 3:05 – 4:05 pm
Speakers: YoungYoon Ham, PharmD, BCIDP, OHSU, Infectious Disease and Antibiotic Allergy Pharmacist; Danielle Boschetto, PharmD, BCTXP, OHSU, Solid Organ Transplant Clinical Pharmacist
Activity-Type: Knowledge-based
Credit Hours: 1.0 (0.1 CEUs)
Learning Objectives:
1. Identify commonly used transplant medications, how their mechanisms may contribute to adverse effects, and ways to minimize complications
2. Describe commonly observed infections and how treatment differs in a transplant recipient
3. Describe the impact of drug-drug interactions with transplant immunosuppression

Title: Keeping Patients Safer with an Opioid Taper (Track A)
UAN: 0036-9999-25-209-L08-P and 0036-9999-25-210-L08-T
Date & Time: Saturday, 4/26/25, 4:10 – 5:10 pm
Speakers: Mindee Dewitt, PharmD, BCGP, FASCP, Kaiser Permanente, Pain Management Clinical Pharmacy Specialist; Darlene Marsh, PharmD, BCACP, Kaiser Permanente, Pain Management Clinical Pharmacy Specialist
Activity-Type: Application-based for RPh, Knowledge-based for CPT
Credit Hours: 1.0 (0.1 CEUs)
Learning Objectives:
1. Identify patient populations that may benefit from opioid tapering
2. Describe potential opioid withdrawal side effects and management options
3. Discuss non-opioid and nonpharmacologic modalities for management of chronic pain
4. (RPh ONLY) Using patient cases, construct a recommendation for deprescribing opioids

Title: Optimizing Strategies and Approaches for Treatment-Resistant Depression (Track B)
UAN: 0036-9999-25-211-L01-P/T
Date & Time: Saturday, 4/26/25, 4:10 – 5:10 pm
Speakers: Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP, Pacific University School of Pharmacy, Dean and Professor
Activity-Type: Knowledge-based
Credit Hours: 1.0 (0.1 CEUs)
RPh Learning Objectives:
1. Define treatment-resistant depression (TRD)
2. Recognize and differentiate pseudo resistance from a true TRD, and identify factors contributing to inadequate treatment response
3. Evaluate and apply evidence-based strategies and treatment approaches for managing TRD
CPT Learning Objectives:
1. Define treatment-resistant depression (TRD)
2. Recognize common reasons why depression treatments may not work as expected
3. Discuss basic treatment strategies and approaches for management of TRD

Title: Chronic Disease Management for Older Adults
UAN: 0036-9999-25-212-L01-P/T
Date & Time: Sunday, 4/27/25, 8:00 – 9:00 am
Speakers: Danielle Backus, PharmD, BCGP, Pacific University Oregon, Associate Professor of Pharmacy Practice; John Begert, PharmD, BCACP, OHSU, Clinical Pharmacist
Activity-Type: Knowledge-based
Credit Hours: 1.0 (0.1 CEUs)
Learning Objectives:
1. Implement strategies to reduce medication administration burden for commonly prescribed medications for older people
2. Identify relevant drug-drug and drug-disease interactions for medications used to treat common chronic diseases in older people
3. Formulate pharmacotherapy assessments and plans incorporating guideline recommendations for common chronic diseases in older people

Title: Clinical Pearls
UAN: 0036-9999-25-213-L01-P/T
Date & Time: Sunday, 4/27/25, 9:05 – 10:05 am
Speakers: Katherine Marks, PharmD, Roseburg VA Health Care System, PGY2 Ambulatory Care Pharmacy Resident; Phuong Y Duong, PharmD, MBA, BCPS, OSU College of Pharmacy, Clinical Assistant Professor; Madeline Tyler, PharmD, Roseburg VA Health Care System, PGY1 Pharmacy Resident; Hanna Kirwan, PharmD, Roseburg VA Health Care System, PGY1 Pharmacy Resident
Activity-Type: Knowledge-based
Credit Hours: 1.0 (0.1 CEUs)
RPh Learning Objectives:
1. (Marks) Assess the associated risk of GU infections with SGLT2i use in patients with and without diabetes
2. (Marks) Consider implications of SGLT2i use in clinical practice for patients with GU infections
3. (Duong) Describe the process of inducting buprenorphine using micro-dosing strategy considering patient’s history of illicit drug use
4. (Duong) Identify buprenorphine dosing range used in micro-dosing induction
5. (Tyler) Describe the impact and prevalence of medication nonadherence
6. (Tyler) Implement evidence-based strategies to improve adherence in clinical practice
7. (Kirwan) Summarize key counseling points for patients who are about to travel with medications
8. (Kirwan) Explain to patients how to properly store medications and documentation of medications while traveling
CPT Learning Objectives:
1. (Marks) Assess the associated risk of GU infections with SGLT2i use in patients with and without diabetes
2. (Marks) Consider implications of SGLT2i use in clinical practice for patients with GU infections
3. (Duong) Identify buprenorphine dosing range used in micro-dosing induction
4. (Tyler) Describe the impact and prevalence of medication nonadherence
5. (Tyler) Implement evidence-based strategies to improve adherence in clinical practice
6. (Kirwan) Identify medications that require more precise handling
7. (Kirwan) Discuss important information to ask patients in order to provide an adequate supply of medications

Title: Mapping Cause Analysis: Who, What, How, and Why
UAN: 0036-9999-25-214-L05-P/T
Date & Time: Sunday, 4/27/25, 10:10 – 11:10 am
Speakers: Katie Hufft, PharmD, BCPS, Medication Safety Officer, Providence Medical Group Oregon
Activity-Type: Knowledge-based
Credit Hours: 1.0 (0.1 CEUs)
State Requirement: Patient Safety
Learning Objectives:
1. Breakdown the elements of a causal statement
2. Identify tools used to uncover the root cause of an error
3. Demonstrate how cause analysis can identify systemic risk and inform action planning to improve medication safety

Title: Board of Pharmacy Law Update
UAN: 0036-9999-25-215-L03-P/T
Date & Time: Sunday, 4/27/25, 11:20 am – 12:20 pm
Speakers: Gary Runyon, PharmD, Oregon Board of Pharmacy, Pharmacist Consultant; Jane Lee, PharmD, RPh, Oregon Board of Pharmacy, Compliance Officer
Activity-Type: Knowledge-based
Credit Hours: 1.0 (0.1 CEUs)
State Requirement: Law
Learning Objectives:
1. Discuss new laws and recent/proposed rules related to Oregon pharmacy practice
2. Examine unique perspectives from Board staff and member(s) about contemporary issues in pharmacy
3. Review compliance expectations for existing laws and rules created to ensure safe and effective delivery of care
4. Develop strategies to utilize the Board of Pharmacy’s website and available resources